{
    "id": "6217e1ac3a8413c653000031",
    "question": "Is serotonin transported by platelets?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"To answer this question, we need to analyze the given documents and look for information about the transport of serotonin by platelets. According to Document [0], serotonin is taken up rapidly into platelets via the serotonin transporter (SERT), where it is either stored in the dense granules in millimolar concentrations or targeted for degradation. This indicates that platelets do take up serotonin. According to Document [4], serotonin is found in platelets, which are able to concentrate the amine by means of an active serotonin transporter mechanism (SERT) similar to that in the membrane of serotonergic nerve endings. This confirms that platelets do transport serotonin. Therefore, the answer is affirmative.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "Surgery_Schwartz_340",
            "title": "Surgery_Schwartz",
            "content": "5-HT. Once in the plasma, 5-HT is taken up rapidly into platelets via the serotonin transporter (SERT), where it is either stored in the dense granules in millimolar concentrations or targeted for deg-radation. It is interesting that the surface expression of SERT on platelets is sensitive to plasma 5-HT levels, which in turn modulates platelet 5-HT content. Receptors for serotonin are widely distributed in the periphery and are found in the GI tract, cardiovascular system, and some immune cells.172 Serotonin is a potent vasoconstrictor and also modulates cardiac inotropy and chronotropy through nonadrenergic cyclic adenosine mono-phosphate (cAMP) pathways. Serotonin is released at sites of injury, primarily by platelets. Recent work has demonstrated an important role for platelet 5-HT in the local inflammatory response to injury. Using mice that lack the nonneuronal iso-form of tryptophan hydroxylase (Tph1), the rate-limiting step for 5-HT synthesis in the periphery, investigators"
        },
        {
            "id": "Pharmacology_Katzung_1682",
            "title": "Pharmacology_Katzung",
            "content": "The function of serotonin in enterochromaffin cells is not fully understood. These cells synthesize serotonin, store the amine in a complex with adenosine triphosphate (ATP) and other substances in granules, and release serotonin in response to mechanical and neuronal stimuli. This serotonin interacts in a paracrine fashion with several different 5-HT receptors in the gut (see Chapter 62). Some of the released serotonin diffuses into blood vessels and is taken up and stored in platelets."
        },
        {
            "id": "Histology_Ross_1425",
            "title": "Histology_Ross",
            "content": "Serotonin is a potent vasoconstrictor that causes the vascular smooth muscle cells to contract, thereby reducing local blood flow at the site of injury. Adenosine diphosphate (ADP), a nucleotide, and the signaling molecule thromboxane A2, are responsible for further aggregation of platelets into a primary hemostatic plug. The mass of aggregated platelets stop extravasation of blood. At the same time, the activated platelets release their and granules, which contain among other substances coagulation factors such as platelet thromboplastic factor (PF3) and additional serotonin. The glycocalyx of the platelets provides a reaction surface for the conversion of soluble fibrinogen into fibrin. Fibrin then forms a loose mesh over the initial plug and is further FIGURE 10.15 \u2022 Scanning electron micrograph of blood clot."
        },
        {
            "id": "Pharmacology_Katzung_1698",
            "title": "Pharmacology_Katzung",
            "content": "Serotonin also constricts veins, and venoconstriction with increased capillary filling appears to be responsible for the flush that is observed after serotonin administration or release from a carcinoid tumor. Serotonin has small direct positive chronotropic and inotropic effects on the heart, which are probably of no clinical significance. However, prolonged elevation of the blood level of serotonin (which occurs in carcinoid syndrome) is associated with pathologic alterations in the endocardium (subendocardial fibroplasia), which may result in valvular or electrical malfunction. Serotonin causes blood platelets to aggregate by activating 5-HT2 receptors. This response, in contrast to aggregation induced during normal clot formation, is not accompanied by the release of serotonin stored in the platelets. The physiologic role of this effect is unclear."
        },
        {
            "id": "Pharmacology_Katzung_1679",
            "title": "Pharmacology_Katzung",
            "content": "After synthesis, the free amine is stored in vesicles or is rapidly inactivated, usually by oxidation by monoamine oxidase (MAO). In the pineal gland, serotonin serves as a precursor of melatonin, a melanocyte-stimulating hormone that has complex effects in several tissues. In mammals (including humans), over 90% of the serotonin in the body is found in enterochromaffin cells in the gastrointestinal tract. In the blood, serotonin is found in platelets, which are able to concentrate the amine by means of an active serotonin transporter mechanism (SERT) similar to that in the membrane of serotonergic nerve endings. Once transported into the platelet or nerve ending, 5-HT is concentrated in vesicles by a vesicle-associated transporter (VAT) that is blocked by reserpine. Serotonin is also found in the raphe nuclei of the brainstem, which contain cell bodies of serotonergic neurons that synthesize, store, and release serotonin as a transmitter. Stored serotonin can be depleted by reserpine"
        },
        {
            "id": "Biochemistry_Lippincott_1803",
            "title": "Biochemistry_Lippinco",
            "content": "Degranulation also results in release of serotonin and adenosine diphosphate (ADP) from dense granules. Serotonin causes vasoconstriction. ADP binds to GPCR on the surface of platelets, activating additional platelets. [Note: Some antiplatelet drugs, such as clopidogrel, are ADP-receptor antagonists.] Platelet-derived growth factor (involved in wound healing), VWF, FV, FXIII, and FI are among other proteins released from \u03b1 granules. [Note: Platelet-activating factor (PAF), an ether phospholipid (see p. 202) synthesized by a variety of cell types including endothelial cells and platelets, binds PAF receptors (GPCR) on the surface of platelets and activates them.] 2. Morphologic change: The change in shape of activated platelets from discoidal to spherical with pseudopod-like processes that facilitate platelet\u2013platelet and platelet\u2013surface interactions (Fig. 35.23) is initiated by the release of Ca2+ from dense granules. Ca2+ bound to calmodulin (see p. 133) mediates the activation of"
        },
        {
            "id": "Biochemistry_Lippincott_1001",
            "title": "Biochemistry_Lippinco",
            "content": "C. Serotonin Serotonin, also called 5-hydroxytryptamine (5-HT), is synthesized and/or stored at several sites in the body (Fig. 21.18). The largest amount by far is found in the intestinal mucosa. Smaller amounts occur in the CNS, where it functions as a neurotransmitter, and in platelets (see online Chapter 35). Serotonin is synthesized from tryptophan, which is hydroxylated in a BH4 requiring reaction analogous to that catalyzed by phenylalanine hydroxylase. The product, 5-hydroxytryptophan, is decarboxylated to 5HT. Serotonin has multiple physiologic roles including pain perception and regulation of sleep, appetite, temperature, blood pressure, cognitive functions, and mood (causes a feeling of well-being). [Note: Selective serotonin reuptake inhibitors (SSRI) maintain serotonin levels, thereby functioning as antidepressants.] Serotonin is degraded by MAO to 5hydroxy-3-indoleacetic acid (5-HIAA). D. Creatine"
        },
        {
            "id": "Neurology_Adams_1374",
            "title": "Neurology_Adams",
            "content": "In part to address the action of the serotonin agonist drugs on migraine (see below), a body of evidence has been assembled that serotonin (5-HT) acts as a humoral mediator in the neural and vascular components of migraine headache. Serotonin is discharged from platelets at the onset of headache and the headache is reduced by the injection of 5-HT. This led to the development by Humphrey of sumatriptan, which acted selectively on 5-HT1B/D receptors so as to reduce side effects. This was the forerunner of the large group of \u201ctriptans.\u201d More recently, nitric oxide generated by endothelial cells has been implicated as the cause of the pain of migraine headache, but the reason for its release and the relationship to changes in blood flow is unclear."
        },
        {
            "id": "Pathology_Robbins_420",
            "title": "Pathology_Robbins",
            "content": "Serotonin (5-hydroxytryptamine) is a preformed vasoactive mediator present in platelets and certain neuroendocrine cells, such as in the gastrointestinal tract, and in mast cells in rodents but not humans. Its primary function is as a neurotransmitter in the gastrointestinal tract. It also is a vasoconstrictor, but the importance of this action in inflammation is unclear."
        },
        {
            "id": "Biochemistry_Lippincott_1813",
            "title": "Biochemistry_Lippinco",
            "content": "platelets. Activated platelets release substances that cause vasoconstriction (serotonin and thromboxane A2 [TXA2]), recruit and activate other platelets (adenosine diphosphate and TXA2), and support the formation of a fibrin clot (FV, FXIII, and fibrinogen). Activation causes changes in platelets that lead to their aggregation. Structural changes in a surface receptor (GPIIb/IIIa) expose binding sites for fibrinogen. Fibrinogen molecules link activated platelets to one another. The fibrinogen is activated to fibrin by thrombin and then cross-linked by FXIIIa coming both from the blood and from platelets. The initial loose plug of platelets (primary hemostasis) is strengthened by the fibrin meshwork (secondary hemostasis). Disorders of platelets and coagulation proteins can result in deviations in the ability to clot. Prothrombin time (PT) and activated partial thromboplastin time (aPTT) are clinical laboratory tests used to evaluate the clotting cascade."
        },
        {
            "id": "Pharmacology_Katzung_3812",
            "title": "Pharmacology_Katzung",
            "content": "Platelet function is regulated by three categories of substances. The first group consists of agents generated outside the platelet that interact with platelet membrane receptors, eg, catecholamines, collagen, thrombin, and prostacyclin. The second category contains agents generated within the platelet that interact with membrane receptors, eg, ADP, prostaglandin D2, prostaglandin E2, and serotonin. A third group comprises agents generated within the platelet that act within the platelet, eg, prostaglandin endoperoxides and thromboxane A2, the cyclic nucleotides cAMP and cGMP, and calcium ion. From this list of agents, several targets for platelet inhibitory drugs have been identified (Figure 34\u20131): inhibition of prostaglandin synthesis (aspirin), inhibition of ADP-induced platelet aggregation (clopidogrel, prasugrel, ticlopidine), and blockade of glycoprotein IIb/IIIa (GP IIb/IIIa) receptors on platelets (abciximab, tirofiban, and eptifibatide). Dipyridamole and cilostazol are"
        },
        {
            "id": "Histology_Ross_1424",
            "title": "Histology_Ross",
            "content": "second type of membrane channel. The DTS contains an electron-dense material originating from the rough endoplasmic reticulum of the megakaryocyte, which serves as a storage site for calcium ions. DTS channels do not connect with the surface of the platelet; however, both the OCS and DTS fuse in various areas of the platelet to form membrane complexes that are important in regulation of the intraplatelet calcium concentration. Platelets function in continuous surveillance of blood vessels, blood clot formation, and repair of injured tissue. Platelets are involved in several aspects of hemostasis (control of bleeding). They continuously survey the endothelial lining of blood vessels for gaps and breaks. When a blood vessel wall is injured or broken, the exposed connective tissue at the damaged site promotes platelet adhesion. Adhesion of the platelets at the damaged site triggers their degranulation and release of serotonin, ADP, and thromboxane A2."
        },
        {
            "id": "InternalMed_Harrison_9138",
            "title": "InternalMed_Harrison",
            "content": "Disorders of Platelets and Vessel Wall 728 of HIT. This is especially true in patients who have undergone cardiopulmonary bypass surgery, where approximately 50% of patients develop these antibodies postoperatively. IgG-specific ELISAs increase specificity but may decrease sensitivity. The other assay is a platelet activation assay, most commonly the serotonin release assay, which measures the ability of the patient\u2019s serum to activate platelets in the presence of heparin in a concentration-dependent manner. This test has lower sensitivity but higher specificity than the ELISA. However, HIT remains a clinical diagnosis."
        },
        {
            "id": "Biochemistry_Lippincott_1896",
            "title": "Biochemistry_Lippinco",
            "content": "synthesis of steroid hormones, bile acids, and vitamin D. Reactive oxygen species are reduced by glutathione peroxidase as glutathione is oxidized. RQ3.Answer = C. Serotonin is released by activated platelets and causes vasoconstriction and platelet aggregation. [Note: Platelets do not synthesize serotonin, but they take up that which was made in the intestine and secreted into the blood.] Serotonin is associated with a feeling of well-being. It is degraded to 5-hydroxyindoleacetic acid by monoamine oxidase that catalyzes oxidative deamination. It is catechol-O-methyltransferase that catalyzes the methylation step in the degradation of the catecholamines. Serotonin is synthesized from tryptophan in a two-step process that utilizes tetrahydrobiopterin (BH4) requiring tryptophan hydroxylase and a pyridoxal phosphate (PLP)-requiring decarboxylase (see figure at right). RQ4.Answer = B. The exocrine pancreas secretes enzymes required for the digestion of dietary carbohydrate, protein, and"
        },
        {
            "id": "InternalMed_Harrison_24537",
            "title": "InternalMed_Harrison",
            "content": "Smooth-muscle contraction, increased vascular permeability Chemotactic attraction of eosinophils Activates platelets to secrete serotonin and other mediators: smooth-muscle contraction; induces vascular permeability Chemotactic attraction of neutrophils Chemotactic attraction of neutrophils Anticoagulant Cleaves kininogen to form bradykinin Clearance of"
        },
        {
            "id": "InternalMed_Harrison_9378",
            "title": "InternalMed_Harrison",
            "content": "Evaluate for thrombosis, particularly deep vein thrombosis. Abbreviation: INR, international normalized ratio. The diagnosis of HIT is established using enzyme-linked assays to detect antibodies against heparin-PF4 complexes or with platelet activation assays. Enzyme-linked assays are sensitive but can be positive in the absence of any clinical evidence of HIT. The most specific diagnostic test is the serotonin release assay. This test is performed by quantifying serotonin release when washed platelets loaded with labeled serotonin are exposed to patient serum in the absence or presence of varying concentrations of heparin. If the patient serum contains the HIT antibody, heparin addition induces platelet activation and serotonin release."
        },
        {
            "id": "InternalMed_Harrison_9280",
            "title": "InternalMed_Harrison",
            "content": "FIGURE 142-1 Platelet activation and thrombosis. Platelets circulate in an inactive form in the blood vessel wall exposes subendothelial vasculature. Damage to the endothelium and/or external stimuli activates platelets that adhere von Willebrand factor and collagen to the to the exposed subendothelial von Willebrand factor and collagen. This adhesion leads to activa-circulating blood. The GPIb-IX-V comtion of the platelet, shape change, and the synthesis and release of thromboxane (TxA2), serotonin plex binds to the exposed von Willebrand (5-HT), and adenosine diphosphate (ADP). Platelet stimuli cause conformational change in the factor, causing platelets to adhere (Fig. platelet integrin glycoprotein (GP) IIb/IIIa receptor, leading to the high-affinity binding of fibrino-142-1). In addition, the engagement of the gen and the formation of a stable platelet thrombus. GPIb-IX-V complex with ligand induces 742 signaling pathways that lead to platelet activation. von Willebrand"
        },
        {
            "id": "Pathology_Robbins_606",
            "title": "Pathology_Robbins",
            "content": "Fig. 4.5 Platelets play a critical role in hemostasis by forming the primary plug that initially seals vascular defects and by providing a surface that binds and concentrates activated coagulation factors. Platelets are disc-shaped anucleate cell fragments that are shed from megakaryocytes in the bone marrow into the bloodstream. Their function depends on several glycoprotein receptors, a contractile cytoskeleton, and two types of cytoplasmic granules. \u03b1-Granules have the adhesion molecule P-selectin on their membranes (Chapter 3) and contain proteins involved in coagulation, such as fibrinogen, coagulation factor V, and vWF, as well as protein factors that may be involved in wound healing, such as fibronectin, platelet factor 4 (a heparin-binding chemokine), platelet-derived growth factor (PDGF), and transforming growth factor-\u03b2. Dense (or \u03b4) granules contain adenosine diphosphate (ADP) and adenosine triphosphate, ionized calcium, serotonin, and epinephrine."
        },
        {
            "id": "Pharmacology_Katzung_1693",
            "title": "Pharmacology_Katzung",
            "content": "3. Cardiovascular system\u2014Serotonin directly causes the contraction of vascular smooth muscle, mainly through 5-HT2 receptors. In humans, serotonin is a powerful vasoconstrictor except in skeletal muscle and the heart, where it dilates blood vessels."
        },
        {
            "id": "InternalMed_Harrison_9278",
            "title": "InternalMed_Harrison",
            "content": "granules, alpha and dense, are distinguished by their size, abundance, and con tent. Alpha-granules contain soluble coagulation proteins, adhesion molecules, growth factors, integrins, cytokines, and inflammatory modulators. Platelet dense-granules are smaller than alpha-granules and less abundant. Whereas alpha-granules contain proteins that may be more important in the inflammatory response, dense-granules contain high concentrations of small molecules, including adenosine diphosphate (ADP) and serotonin, that influence platelet aggregation."
        },
        {
            "id": "Pharmacology_Katzung_1681",
            "title": "Pharmacology_Katzung",
            "content": "Brain serotonergic neurons are involved in numerous diffuse functions such as mood, sleep, appetite, and temperature regulation, as well as the perception of pain, the regulation of blood pressure, and vomiting (see Chapter 21). Serotonin is clearly involved in psychiatric depression (see Chapter 30) and also appears to be involved in conditions such as anxiety and migraine. Serotonergic neurons are found in the enteric nervous system of the gastrointestinal tract and around blood vessels. In rodents (but not in humans), serotonin is also found in mast cells."
        },
        {
            "id": "Pharmacology_Katzung_3736",
            "title": "Pharmacology_Katzung",
            "content": "FIGURE 34\u20131 Thrombus formation at the site of the damaged vascular wall (EC, endothelial cell) and the role of platelets and clotting factors. Platelet membrane receptors include the glycoprotein (GP) Ia receptor, binding to collagen (C); GP Ib receptor, binding von Willebrand factor (vWF); and GP IIb/IIIa, which binds fibrinogen and other macromolecules. Antiplatelet prostacyclin (PGI2) is released from the endothelium. Aggregating substances released from the degranulating platelet include adenosine diphosphate (ADP), thromboxane A2 (TXA2), and serotonin (5-HT). Production of factor Xa by intrinsic and extrinsic pathways is detailed in Figure 34\u20132. (Redrawn and reproduced, with permission, from Simoons ML, Decker JW: New directions in anticoagulant and antiplatelet treatment. [Editorial.] Br Heart J 1995;74:337.) aggregation and vasoconstriction. Activation of platelets results in a conformational change in the \u03b1IIb\u03b2III integrin (IIb/IIIa) receptor, enabling it to bind fibrinogen,"
        },
        {
            "id": "Pharmacology_Katzung_1677",
            "title": "Pharmacology_Katzung",
            "content": "Before the identification of 5-hydroxytryptamine (5-HT), it was known that when blood is allowed to clot, a vasoconstrictor (tonic) substance is released from the clot into the serum. This substance was called serotonin. Independent studies established the existence of a smooth muscle stimulant in intestinal mucosa. This was called enteramine. The synthesis of 5-hydroxytryptamine in 1951 led to the identification of serotonin and enteramine as the same metabolite of 5-hydroxytryptophan. Serotonin is an important neurotransmitter, a local hormone in the gut, a component of the platelet clotting process, and is thought to play a role in migraine headache and several other clinical conditions, including carcinoid syndrome. This syndrome is an unusual manifestation of carcinoid tumor, a neoplasm of enterochromaffin cells. In patients whose tumor is not surgically resectable, a serotonin antagonist may constitute a useful treatment."
        },
        {
            "id": "Biochemistry_Lippincott_1812",
            "title": "Biochemistry_Lippinco",
            "content": "Wound to a tissue damages blood vessels and exposes collagen. Platelets (thrombocytes) adhere to the exposed collagen, get activated, and aggregate to form a platelet plug. Adhesion is mediated by von Willebrand factor (VWF). VWF binds collagen, and platelets bind VWF via glycoprotein Ib (GPIb) within a receptor complex on the platelet surface. Deficiency of VWF results in von Willebrand disease, the most common inherited coagulopathy. Once adhered, platelets get activated. Platelet activation involves changes in shape (discoidal to spherical with pseudopodia) and degranulation, the process by which platelets release the contents of their storage granules. Thrombin is the most potent activator of platelets. Thrombin binds to protease-activated G protein\u2013coupled receptors on the surface of platelets. Activated platelets release substances that cause vasoconstriction (serotonin and thromboxane A2 [TXA2]), recruit and activate other platelets (adenosine diphosphate and TXA2), and support"
        },
        {
            "id": "Pharmacology_Katzung_3735",
            "title": "Pharmacology_Katzung",
            "content": "The vascular endothelial cell layer lining blood vessels has an anticoagulant phenotype, and circulating blood platelets and clotting factors do not normally adhere to it to an appreciable extent. In the setting of vascular injury, the endothelial cell layer rapidly undergoes a series of changes resulting in a more procoagulant phenotype. Injury exposes reactive subendothelial matrix proteins such as collagen and von Willebrand factor, which results in platelet adherence and activation, and secretion and synthesis of vasoconstrictors and platelet-recruiting and activating molecules. Thus, thromboxane A2 (TXA2) is synthesized from arachidonic acid within platelets and is a platelet activator and potent vasoconstrictor. Products secreted from platelet granules include adenosine diphosphate (ADP), a powerful inducer of platelet aggregation, and serotonin (5-HT), which stimulates"
        },
        {
            "id": "InternalMed_Harrison_4506",
            "title": "InternalMed_Harrison",
            "content": "Platelet adhesion results in subsequent platelet activation and aggregation. This process is enhanced and amplified by humoral mediators in plasma (e.g., epinephrine, thrombin); mediators released from activated platelets (e.g., adenosine diphosphate, serotonin); and vessel wall extracellular matrix constituents that come in contact with adherent platelets (e.g., collagen, VWF). Activated platelets undergo the release reaction, during which they secrete contents that further promote aggregation and inhibit the naturally anticoagulant endothelial cell factors. During platelet aggregation (platelet-platelet interaction), additional platelets are recruited from the circulation to the site of vascular injury, leading to the formation of an occlusive platelet thrombus. The platelet plug is anchored and stabilized by the developing fibrin mesh."
        },
        {
            "id": "InternalMed_Harrison_7244",
            "title": "InternalMed_Harrison",
            "content": "Patients may develop either a typical or, rarely, an atypical carcinoid syndrome (Fig. 113-1). In patients with the typical form, which characteristically is caused by midgut NETs (carcinoids), the conversion of tryptophan to 5-HTP is the rate-limiting step (Fig. 113-1). Once 5-HTP is formed, it is rapidly converted to 5-HT and stored in secretory granules of the tumor or in platelets. A small amount remains in plasma and is converted to 5-HIAA, which appears in large amounts in the urine. These patients have an expanded serotonin pool size, increased blood and platelet serotonin, and increased urinary 5-HIAA. Some GI-NETs (carcinoids) cause an atypical carcinoid syndrome that is thought to be due to a deficiency in the enzyme dopa decarboxylase; thus, 5-HTP cannot be converted to 5-HT (serotonin), and 5-HTP is secreted into the bloodstream (Fig. 113-1). In these patients, plasma serotonin levels are normal but urinary levels may be increased because some 5-HTP is converted to 5-HT in"
        },
        {
            "id": "Surgery_Schwartz_712",
            "title": "Surgery_Schwartz",
            "content": "to prostaglandin H2 (PGH2), which, in turn, is converted to TXA2. TXA2 has potent vasoconstriction and platelet aggrega-tion effects. Arachidonic acid may also be shuttled to adjacent endothelial cells and converted to prostacyclin (PGI2), which is a vasodilator and acts to inhibit platelet aggregation. Platelet cyclooxygenase is irreversibly inhibited by aspirin and revers-ibly blocked by nonsteroidal anti-inflammatory agents but is not affected by cyclooxygenase-2 (COX-2) inhibitors.In the second wave of platelet aggregation, a release reaction occurs in which several substances including ADP, Ca2+, serotonin, TXA2, and \u03b1-granule proteins are discharged. Biology of Hemostasis 103Vascular Constriction / 103Platelet Function / 103Coagulation / 104Fibrinolysis / 106Congenital Factor Deficiencies 106Coagulation Factor Deficiencies / 106Platelet Functional Defects / 107Acquired Hemostatic Defects 108Platelet Abnormalities / 108Acquired Hypofibrinogenemia / 110Myeloproliferative Diseases"
        },
        {
            "id": "Neurology_Adams_8360",
            "title": "Neurology_Adams",
            "content": "diagonal band of Broca (located in the basal frontal and septal region), as well as in the cerebellar nuclei and inferior olive. The latter changes were inferred from studying the brains of autistic children who died at different ages, and they gave the appearance of a progressive or ongoing pathology that continues into adult life. These findings are in keeping with the concept of autism as a neurodevelopmental disorder, but they allow only speculation regarding the derivation of the clinical features of the disease. An increased concentration of platelet serotonin and low serum serotonin is detected in many but not all patients; also, serum oxytocin is reduced. The biologic significance of these findings is unclear."
        },
        {
            "id": "InternalMed_Harrison_7236",
            "title": "InternalMed_Harrison",
            "content": "One of the main secretory products of GI-NETs (carcinoids) involved in the carcinoid syndrome is serotonin (5-HT) (Fig. 113-1), which is synthesized from tryptophan. Up to 50% of dietary tryptophan can be used in this synthetic pathway by tumor cells, and this can result in inadequate supplies for conversion to niacin; hence, some patients (2.5%) develop pellagra-like lesions. Serotonin has numerous biologic effects, including stimulating intestinal secretion with inhibition of absorption, stimulating increases in intestinal motility, and stimulating fibrogenesis. In various studies, 56\u201388% of all GI-NETs (carcinoids) were associated with serotonin overproduction; however, 12\u201326% of the patients did not have the carcinoid syndrome. In one study, platelet serotonin was elevated in 96% of patients with midgut NETs (carcinoids), 43% with foregut tumors, and 0% with hindgut tumors. In 90\u2013100% of patients with the carcinoid syndrome, there is evidence of serotonin overproduction. Serotonin"
        },
        {
            "id": "Surgery_Schwartz_711",
            "title": "Surgery_Schwartz",
            "content": "von Willebrand factor (vWF), a protein in the subendothelium that is lacking in patients with von Willebrand\u2019s disease. vWF binds to glycopro-tein (GP) I/IX/V on the platelet membrane. Following adhesion, platelets initiate a release reaction that recruits other platelets from the circulating blood to seal the disrupted vessel. Up to this point, this process is known as primary hemostasis. Platelet aggregation is reversible and is not associated with secretion. Additionally, heparin does not interfere with this reaction, and thus, hemostasis can occur in the heparinized patient. Adenosine diphosphate (ADP) and serotonin are the principal mediators in platelet aggregation.Arachidonic acid released from the platelet membranes is converted by cyclooxygenase to prostaglandin G2 (PGG2) and then to prostaglandin H2 (PGH2), which, in turn, is converted to TXA2. TXA2 has potent vasoconstriction and platelet aggrega-tion effects. Arachidonic acid may also be shuttled to adjacent endothelial"
        },
        {
            "id": "Neurology_Adams_12169",
            "title": "Neurology_Adams",
            "content": "serotonin antidepressants) that were associated with a sevenfold increased risk of major depression. Not all studies agree on these points. This result has been reinforced by Caspi and colleagues who reported that a variant in the serotonin transporter correlates with an increase in depression in response to stress. Other hypotheses have postulated various susceptibility loci but again, a single gene locus seems unlikely (see Sanders et al)."
        }
    ],
    "scores": [
        0.0383583907583887,
        0.038168023349289135,
        0.03658614113159568,
        0.03650752155425053,
        0.03649324675568421,
        0.03456680043384811,
        0.03442823445307744,
        0.0325934221856057,
        0.03211871655470943,
        0.03193895108000773,
        0.03159044177623274,
        0.02873236653586389,
        0.028060550949171804,
        0.027367965133591403,
        0.026475742878654698,
        0.026282051282051282,
        0.025763125763125765,
        0.024922202435558434,
        0.024678925369109418,
        0.024575205202004048,
        0.024428672103090708,
        0.02389764274313015,
        0.02357678164129777,
        0.022872419176828446,
        0.022824754901960783,
        0.022705849271537147,
        0.022619883040935672,
        0.02258454106280193,
        0.021721933379577896,
        0.02104629831325175,
        0.020819447686498103,
        0.02029260907180818
    ]
}